[PRACTICE NOTE] Dr. Roswell and Her Other Life: Resetting Pharma’s Experiential Benchmark.
[PRACTICE NOTE] Dr. Roswell and Her Other Life: Resetting Pharma’s Experiential Benchmark.
Part One: The New HCP Customer Context
Dr. Karen Roswell, a cardiologist, begins her day in a world that knows her. Before she interacts with a single patient, she is already moving through a series of quietly orchestrated moments shaped by the companies that define the global standard for modern living. Her Tesla prepares the route to the hospital, analyzes traffic, and alerts her to delays before she even thinks to check. Her Spotify playlist adjusts to her mood. Her Starbucks mobile order is waiting on the counter because the system has learned her rhythm. Her iPhone calendar synchronizes across devices without requiring her attention. Her Instacart delivery has been predicted and scheduled for a time that fits her evening.
These moments are not indulgences. They are the invisible architecture of her other life as a high-expectation consumer, and they teach her that consistency should be silent, anticipation should be normal, and friction should be rare. None of this feels extraordinary anymore. It feels expected. It shapes her definition of what competence and respect for her time look like. It teaches her that anticipation is empathy, that clarity is possible, and that friction is a choice. She does not shed these lessons when she enters her clinical practice. On behalf of her patients, support staff and colleagues she carries them with her because they have become part of how she interprets trust, care, and professionalism.
A high-expectation consumer is shaped by the world’s best experience brands. She expects every interaction—personal or professional—to be personalized, effortless, predictive, consistent, and human. Her benchmark is no longer set by your industry, but by her other life as a consumer.
This is The New HCP Customer Context.
The Continuous World of Expectation
She does not possess two sets of expectations, one for her consumer life and another for her clinical life. She moves through one continuous world where the best experiences she encounters anywhere inform the standard she expects everywhere. When she books a last-minute flight through Delta’s app and watches the entire process compress into a few simple, reassuring steps, she learns that orchestration is possible. When her financial life is managed through American Express, which anticipates her next move and surfaces what she needs before she looks for it, she learns that personalization is possible. When Netflix delivers recommendations that feel perfectly attuned to her preferences, she learns that relevance is possible.
These experiences accumulate into an instinctive baseline. They shape her expectations long before she sees her first patient, and they follow her through every door she walks through that day.
The Sharp Contrast
The shift is not subtle when she enters the pharmaceutical ecosystem. It is abrupt. It is jarring. She moves from an environment that understands her without asking to one that seems unaware she exists at all. The first pharma portal she opens greets her not with recognition but with a demand to reenter information she has already provided. A clinical resource she urgently needs is buried in a labyrinth of tabs designed for someone else’s convenience. A patient support program requests redundant details. A reimbursement form requires her staff to print and fax documentation that feels almost surreal in a world where everything else works with a single tap.
None of these moments are crises, but together they carry weight. Each one steals time and energy. Each one sends a quiet message that her effort is assumed rather than valued. The contrast is emotional, not conceptual. It is physical. It manifests as a tightening in the chest and a fog that lingers. As The Customer Excellence Enterprise notes, it becomes “a numbing effect on the human spirit.” It shapes how she feels about brands before she considers a single claim about efficacy or safety. It determines whether she perceives the company as a partner in care or another source of administrative friction.
Once this feeling forms, it becomes part of her memory and part of her story of the company. It rarely fades because her other life constantly reminds her that things can be better. Every seamless interaction elsewhere reinforces the gap she experiences here. Every moment of ease in her consumer world becomes proof that friction in healthcare is not inevitable. It is designed. It is a choice.
Experiential Commerce and the Rising Bar of Expectation
What she experiences is not an isolated inconvenience. It is the predictable outcome of a world reshaped by Experiential Commerce, where value is defined not only by what a product does or what a company says about it but by how it is delivered, understood, accessed, and lived. Apple, Amazon, Delta, Nike, and Emirates have proven that experience itself is a unit of value, one that can elevate or diminish the product and brand proposition long before a feature is used or a benefit realized.
Customers are not merely buying devices, flights, or services. They are buying the feeling of ease, confidence, and respect that surrounds those offerings. These companies have shown that the experience is inseparable from the product, the journey inseparable from the outcome, and the delivery inseparable from the promise. In intensely competitive environments such as pharma, where efficacy and safety are table stakes, experience can rise to become the decisive factor, the element that earns preference, trust, and long-term loyalty.
Our cardiologist, Dr. Roswell, is not simply enjoying convenience or seeking delight. She is internalizing a new economic logic and articulating a new standard of care. When an organization respects her time, she trusts it more deeply. When it orchestrates complexity on her behalf, she becomes loyal. These lessons dissolve the boundaries between industries. They reshape her expectations of how any company should behave, including those in healthcare.
Ease now signals credibility. Coherence signals competence. Respect for her time signals respect for her role in patient care.
Technology Parity and the Limits of Modernization
Pharma has not been passive. It has invested heavily in digital platforms, omnichannel engines, personalization tools, and now AI-driven orchestration systems. Yet healthcare professionals experience little of the progress that leaders believe they have made. The expansion of tech stacks has expanded complexity. Every new channel becomes another place for a message to land without coherence. Every new platform creates another point where context is lost.
The pharma industry’s instinct has been to modernize by addition: more channels, more content, more dashboards, more automation. But when the underlying structures remain company-centric and fragmented, every new tool amplifies the noise and the cognitive load on HCPs. Modernization becomes activity without direction. Customers do not feel infrastructure; they feel coherence, continuity, and care. When those qualities are missing, tech becomes a multiplier of burden and friction rather than a creator of value.
DTC Healthcare and the Redefinition of What Is Possible
Direct to consumer healthcare innovators such as Ro, Hims and Hers, Thirty Madison, and Amazon Clinic are redefining what is possible by designing seamless end to end journeys where experience is the operating system. They demonstrate that clarity, continuity, and speed are not luxuries; they are the conditions of participation in modern care.
Even their advertising delivers an experiential message. Hims and Hers, for example, does not lead with clinical data or product specifics. It leads with reassurance, simplicity, and immediacy: “A visit starts in minutes. Results delivered to your door.” Amazon Clinic takes the same approach, showing customers how effortless care can be with headlines like “Care that fits into your life” and interfaces that mirror the frictionless design of Prime. These brands are selling not just healthcare, but the feeling of modern care that is accessible, human, and seamlessly orchestrated.
A patient who experiences this kind of design learns that fragmentation is not inevitable. A caregiver realizes that the burden of navigation can be carried by the provider rather than by the family. An HCP observing this model understands that many barriers in traditional therapy delivery are the result of outdated design, not immovable constraint. Once these models enter the cultural imagination, they reset the baseline for what healthcare should feel like. It is no surprise, then, that HCPs are beginning to ask a confounding question: if emerging startups can deliver this level of simplicity and humanity, why can’t the multi billion dollar pharmaceutical companies, with all their resources and sophistication, do the same?
Pharma’s Consumer-Grade Imperative
Together these forces converge into a single truth. Pharmaceutical engagement is no longer judged against other pharma companies. It is judged against the best experiences in a customer’s life. Transcending industry boundaries, every seamless interaction with Apple, Amazon, or Emirates becomes part of the benchmark she carries into her workday. She does not evaluate pharma through the lens of regulation or industry norms. She evaluates it through the lens of modern competence, coherence, and empathy.
This is the Consumer-Grade Imperative.
When she engages with a pharmaceutical brand, she expects systems that know her context, tools that remember her choices, and journeys that respect her time. She expects continuity across field, digital, medical, and access because continuity is how her world works. She expects the engagement to feel as considered as the science itself because design and delivery are now expressions of credibility.
This expectation is not aspirational. It is the new standard. It defines whether breakthrough science achieves its intended impact or falters in the final mile. Those who meet it will set the pace. Those who do not will be left behind.
Part Two: A Different Kind of Pharma Company — The Rise of the Customer Excellence Enterprise
Pharma has built extraordinary scientific systems. Few sectors operate under evidentiary requirements as demanding. Data must withstand scrutiny, manufacturing must meet microscopic tolerances, and documentation must trace every action. These capabilities remain the foundation of trust. Yet the same precision that governs the molecule must now extend to the experience that delivers it. The rigor that protects patients must now also protect the integrity of every interaction. Commercial engagements no longer get a pass, they are part of the total value proposition, and their quality directly shapes how science is perceived, trusted, and adopted.
The physician who trusts the molecule should rightly expects the support ecosystem to display the same reliability. The patient who believes in the integrity of the data expects the access pathway to reflect the same rigor. A perfectly crafted script is meaningless if it never translates into therapy in the hands of the patient. Half of all prescriptions in some therapeutic areas go unfilled because friction—not science—blocks fulfillment.
The future of pharma will be defined by companies that evolve from scientific engines into Customer Excellence Enterprises. A Customer Excellence Enterprise is not a rebranded engagement program or transformation effort layered on top of the old commercial model. It is an organization that rewires its leadership, organizational, operational, and commercial DNA to become predisposed to deliver exceptional experiences, where coherence becomes instinctive.
Predisposition replaces aspiration. The company no longer tries to deliver consistency through ad hoc or reactive tactics; it delivers it by design. It no longer relies on heroics; it embeds excellence structurally and systematically. Trust becomes not a goal but an output of how the enterprise is built.
Customer Excellence Enterprises treat experience quality with the same seriousness as data integrity. They meet the elevated evidentiary standards of science and trust standards of pharma brands with a consumer-grade experiential standard. They organize around journeys rather than silos. They shift from company-centric funnels to customer-centric flywheels. They make scientific value inseparable from human value.
Customer Excellence as the Fourth Pillar
Customer Excellence now stands beside Launch Excellence, Sales Excellence, and Marketing Excellence as the fourth pillar of modern pharmaceutical commercial performance. It does not replace them. It completes them. It turns parallel functions into an integrated commercial operating system.
Customer Excellence strengthens the handoffs that undermine Launch Excellence, brings continuity to the relationships that define Sales Excellence, and delivers coherence to the experiences that Marketing Excellence promises. It becomes the connective fabric that binds all customer-facing activity into one enterprise rhythm.
Fueled by voice of the customer and customer context, it also introduces capabilities the other three pillars cannot. It unites customer engagement, customer success, experience management, and customer care into a single discipline. These functions, once isolated and fragmented, become a unified experience system.
Within this system, engagement becomes anticipatory rather than reactive. Customer success becomes relational rather than transactional. Experience management becomes a strategic compass rather than a reporting tool. Customer care becomes a living expression of brand promise. The customer no longer feels the company in fragments. They feel one coherent enterprise.
Such an evolution extends the rigor of scientific and manufacturing excellence outward. It applies the same discipline used in discovery to the architecture of customer journeys. It applies the same seriousness of manufacturing to the orchestration of access and support. It applies the same ethics of patient safety to the protection of customer trust.
Customer Excellence is how pharma meets the Consumer-Grade Imperative. It is how science earns its impact through systems that are as intelligent, credible, and empathetic as the science itself.
Part Three: A Rebellion Beyond the Remit of Marketing
Transformation, as practiced by most organizations, is finite. It has budgets, governance, and endpoints. It updates tools but rarely challenges the assumptions that created fragmentation in the first place. Transformation modernizes without unsettling.
Customer Excellence demands something more courageous. It demands a rebellion.
A rebellion has no end state. It is a sustained refusal to accept the limits of the status quo. It challenges the orthodoxy that keeps pharma anchored to outdated habits. It replaces inertia with movement and passivity with purpose.
This rebellion must be led by those commercial players closest to the customer. Marketers, CX leaders, field teams, brand teams, medical liaisons, access specialists see the seams where friction accumulates. They hear the exhaustion in a physician’s voice when three portals are required to perform a single task. They feel the weight of administrative burden that erodes care.
Their proximity gives them clarity and responsibility. They know that the Consumer-Grade Imperative cannot be met with yesterday’s models. When they act together, they create the gravitational force that pulls the enterprise forward.
Within this coalition, the CMO becomes the architect of the rebellion. Positioned at the intersection of brand, field, digital, and experience, the CMO sees the entire journey. This vantage point reveals how scientific value is amplified or diminished by the system that surrounds it. The CMO becomes, by necessity, the Chief Customer Officer—the steward of coherence across every interaction.
This rebellion is not about defiance. It is about the responsibility for pharma companies and the individuals,within them to demand more of themselves, driving to be the best version of themselves. It is grounded in the belief that science deserves experiences as intelligent, reliable, and humane as the research behind it. It recognizes that customers do not separate the therapy from the system that delivers it. They feel both as one truth.
Rebellion becomes the antidote to inertia. It turns continuous improvement into instinct and coherence into culture. It ensures that Customer Excellence is not a project but a way of working.
This is the rebellion that will define the next generation of pharmaceutical leadership. It is how science earns permission, experience earns preference, and organizations earn the right to lead with both.
Five Takeaways
1. The new competitive frontier is experiential. Healthcare professionals live in a consumer world where friction is a design flaw, not an inevitability. Pharma must adapt to their new context.
2. Customer Excellence is the structural response. It unifies marketing, sales, and launch excellence into a single system that turns scientific value into lived value.
3. Trust is now engineered, not assumed. Customer Excellence builds trust through design, coherence, and consistency rather than message repetition.
4. Transformation modernizes tools. Rebellion rewires belief. True change occurs when organizations replace compliance-driven logic with customer-driven conviction.
5.
Science earns permission. Experience earns preference. Together they form the foundation of enduring growth in the era of Experiential Commerce.
